Replies to post #161154 on Biotech Values

[DewDiligence]

Bayer’s own PR on the Xofigo approval:

http://finance.yahoo.com/news/bayer-receives-u-fda-approval-154000103.html

Algeta has co-marketing rights in the US; however, trading on the company’s home market in Oslo closed for the day before the announcement of the FDA approval.

[DewDiligence]

WSJ questions Algeta on valuation and Xofigo sales ramp:

http://online.wsj.com/article/SB10001424127887324202304579052760594286386.html

Xofigo's launch could be a slow burn... There may be other logistical hurdles related to Medicare reimbursement and getting physicians from different specialties like oncology and radiology to work together. An alternative to chemotherapy is surely welcome, but a radiopharmaceutical may take time to get traction with doctors and patients.

It certainly wouldn’t be the first time these issues have impeded the commercial uptake of a cancer drug.